Literature DB >> 23195858

Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain.

Gabriela Mellado-Sanchez1, Karina Ramirez, Cinthia B Drachenberg, Jovita Diaz-McNair, Ana L Rodriguez, James E Galen, James P Nataro, Marcela F Pasetti.   

Abstract

Yersinia pestis causes bubonic and pneumonic plague in humans. The pneumonic infection is the most severe and invariably fatal if untreated. Because of its high virulence, ease of delivery and precedent of use in warfare, Y. pestis is considered as a potential bioterror agent. No licensed plague vaccine is currently available in the US. Laboratory research with virulent strains requires appropriate biocontainment (i.e., Biosafety Level 3 (BSL-3) for procedures that generate aerosol/droplets) and secure facilities that comply with federal select agent regulations. To assist in the identification of promising vaccine candidates during the early phases of development, we characterized mouse models of systemic and pneumonic plague infection using the Y. pestis strain EV76, an attenuated human vaccine strain that can be rendered virulent in mice under in vivo iron supplementation. Mice inoculated intranasally or intravenously with Y. pestis EV76 in the presence of iron developed a systemic and pneumonic plague infection that resulted in disease and lethality. Bacteria replicated and severely compromised the spleen, liver and lungs. Susceptibility was age dependent, with younger mice being more vulnerable to pneumonic infection. We used these models of infection to assess the protective capacity of newly developed Salmonella-based plague vaccines. The protective outcome varied depending on the route and dose of infection. Protection was associated with the induction of specific immunological effectors in systemic/mucosal compartments. The models of infection described could serve as safe and practical tools for identifying promising vaccine candidates that warrant further potency evaluation using fully virulent strains in BSL-3 settings.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23195858      PMCID: PMC3594127          DOI: 10.1016/j.cimid.2012.10.005

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  53 in total

Review 1.  Innate immunity and pulmonary host defense.

Authors:  P Zhang; W R Summer; G J Bagby; S Nelson
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

2.  Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies.

Authors:  Alejandra V E Capozzo; Karina Ramírez; John M Polo; Jeffrey Ulmer; Eileen M Barry; Myron M Levine; Marcela F Pasetti
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 3.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

4.  Fatal laboratory-acquired infection with an attenuated Yersinia pestis Strain--Chicago, Illinois, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-02-25       Impact factor: 17.586

5.  Biosafety level 2 model of pneumonic plague and protection studies with F1 and Psa.

Authors:  Estela M Galván; Manoj Kumar Mohan Nair; Huaiqing Chen; Fabio Del Piero; Dieter M Schifferli
Journal:  Infect Immun       Date:  2010-05-24       Impact factor: 3.441

6.  Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis.

Authors:  Hanni Lee-Lewis; Deborah M Anderson
Journal:  Infect Immun       Date:  2009-10-19       Impact factor: 3.441

Review 7.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

8.  Pneumonic plague pathogenesis and immunity in Brown Norway rats.

Authors:  Deborah M Anderson; Nancy A Ciletti; Hanni Lee-Lewis; Derek Elli; Joshua Segal; Kristin L DeBord; Katie A Overheim; Maria Tretiakova; Robert R Brubaker; Olaf Schneewind
Journal:  Am J Pathol       Date:  2009-01-22       Impact factor: 4.307

9.  Hfe deficiency impairs pulmonary neutrophil recruitment in response to inflammation.

Authors:  Karolina Benesova; Maja Vujić Spasić; Sebastian M Schaefer; Jens Stolte; Tomi Baehr-Ivacevic; Katharina Waldow; Zhe Zhou; Ursula Klingmueller; Vladimir Benes; Marcus A Mall; Martina U Muckenthaler
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

Review 10.  Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents - review.

Authors:  M Pohanka; P Skládal
Journal:  Folia Microbiol (Praha)       Date:  2009-10-14       Impact factor: 2.629

View more
  3 in total

1.  A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection.

Authors:  James E Galen; Jin Yuan Wang; Jose A Carrasco; Scott A Lloyd; Gabriela Mellado-Sanchez; Jovita Diaz-McNair; Olga Franco; Amanda D Buskirk; James P Nataro; Marcela F Pasetti
Journal:  Infect Immun       Date:  2014-10-20       Impact factor: 3.441

2.  A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Authors:  Shannon J Heine; Olga L Franco-Mahecha; Khandra T Sears; Cinthia B Drachenberg; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti
Journal:  J Immunol       Date:  2019-02-20       Impact factor: 5.422

3.  Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.

Authors:  Theresa B Gallagher; Gabriela Mellado-Sanchez; Ana L Jorgensen; Stephen Moore; James P Nataro; Marcela F Pasetti; Les W Baillie
Journal:  PLoS Negl Trop Dis       Date:  2019-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.